OncoSec Medical Incorporated, a biotechnology company, engages in developing DNA-based intratumoral immunotherapies in the United States. The company's investigational technology, ImmunoPulseis designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as plasmid encoded IL-12 (tavokinogene telseplasmid or tavo) for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, has demonstrated a favorable safety profile, evidence of anti-tumor activity in the treatment of various solid tumors, and the potential to reach beyond the site of local treatment to initiate a systemic immune response in Phase 1 and 2 clinical trials for metastatic melanoma and triple-negative breast cancer. The company has also completed Phase II studies in metastatic melanoma (OMS-I100) and merkel cell carcinoma (OMS-I110). OncoSec Medical Incorporated has an investigator-sponsored clinical trial with the University of California, San Francisco to evaluate the safety and efficacy of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) in patients with low tumor-infiltrating lymphocyte (OMS-I102); and a clinical trial collaboration and drug supply agreement with Merck (known as MSD outside the United States and Canada) to evaluate the combination of its ImmuoPulse IL-12 with Merck's anti-PD-1 therapy KEYTRUDA (pembrolizumab) in a registration-directed Phase 2b clinical trial referred to as PISCES. This trial would evaluate the combination of therapies in patients with unresectable metastatic melanoma who have progressed. It also has a research collaboration with Avacta Group plc for gene delivery of therapeutic affimers. The company was formerly known as NetVentory Solutions Inc. and changed its name to OncoSec Medical Incorporated in March 2011. OncoSec Medical Incorporated was incorporated in 2008 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ONCS
CUSIPN/A
Phone855-662-6732
Debt
Debt-to-Equity RatioN/A
Current Ratio10.16
Quick Ratio10.16
Price-To-Earnings
Trailing P/E Ratio-1.26
Forward P/E Ratio-1.65
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.49 per share
Price / Book2.84
Profitability
EPS (Most Recent Fiscal Year)($1.06)
Net Income$-21,440,000.00
Net MarginsN/A
Return on Equity-155.69%
Return on Assets-125.35%
Miscellaneous
Employees35
Outstanding Shares52,350,000
Market Cap$69.10 million
OncoSec Medical (NASDAQ:ONCS) Frequently Asked Questions
What is OncoSec Medical's stock symbol?
OncoSec Medical trades on the NASDAQ under the ticker symbol "ONCS."
How were OncoSec Medical's earnings last quarter?
OncoSec Medical Inc (NASDAQ:ONCS) released its earnings results on Wednesday, October, 25th. The biotechnology company reported ($0.28) EPS for the quarter, missing the Zacks' consensus estimate of ($0.23) by $0.05. View OncoSec Medical's Earnings History.
When is OncoSec Medical's next earnings date?
What price target have analysts set for ONCS?
4 Wall Street analysts have issued twelve-month price targets for OncoSec Medical's shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate OncoSec Medical's share price to reach $4.6667 in the next twelve months. This suggests a possible upside of 235.7% from the stock's current price. View Analyst Price Targets for OncoSec Medical.
What is the consensus analysts' recommendation for OncoSec Medical?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoSec Medical in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OncoSec Medical.
Who are some of OncoSec Medical's key competitors?
Some companies that are related to OncoSec Medical include Bellicum Pharmaceuticals (BLCM), Affimed (AFMD), MannKind (MNKD), Xenon Pharmaceuticals (XENE), Kala Pharmaceuticals (KALA), Aratana Therapeutics (PETX), Athersys (ATHX), Axovant Sciences (AXON), Melinta Therapeutics (MLNT), ASLAN PHARMACEUTICALS ADR REP 5 (ASLN), Galectin Therapeutics (GALT), Menlo Therapeutics (MNLO), Ocular Therapeutix (OCUL), Ardelyx (ARDX) and Kamada (KMDA).
Who are OncoSec Medical's key executives?
OncoSec Medical's management team includes the folowing people:
- Dr. Avtar S. Dhillon, Co-Founder & Chairman (Age 57)
- Mr. Punit S. Dhillon B.A., BA, Co-Founder & Director (Age 38)
- Dr. Sharron Gargosky Ph.D., Chief Clinical & Regulatory Officer (Age 54)
- Mr. Daniel J. O'Connor J.D., Pres, CEO & Director (Age 54)
- Ms. Sara M. Bonstein, CFO & COO (Age 37)
Has OncoSec Medical been receiving favorable news coverage?
Media headlines about ONCS stock have been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. OncoSec Medical earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned news stories about the biotechnology company an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View Recent Headlines for OncoSec Medical.
Who are OncoSec Medical's major shareholders?
OncoSec Medical's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Nexthera Capital LP (4.99%), Point72 Asset Management L.P. (4.23%), Millennium Management LLC (2.28%), 683 Capital Management LLC (0.57%), BlackRock Inc. (0.46%) and DRW Securities LLC (0.34%). Company insiders that own OncoSec Medical stock include Avtar S Dhillon, Daniel J O'connor, Punit Dhillon and Richard B Slansky. View Institutional Ownership Trends for OncoSec Medical.
Which institutional investors are selling OncoSec Medical stock?
ONCS stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P.. Company insiders that have sold OncoSec Medical company stock in the last year include Avtar S Dhillon, Punit Dhillon and Richard B Slansky. View Insider Buying and Selling for OncoSec Medical.
Which institutional investors are buying OncoSec Medical stock?
ONCS stock was acquired by a variety of institutional investors in the last quarter, including Nexthera Capital LP, 683 Capital Management LLC, BlackRock Inc., Millennium Management LLC and DRW Securities LLC. Company insiders that have bought OncoSec Medical stock in the last two years include Daniel J O'connor and Punit Dhillon. View Insider Buying and Selling for OncoSec Medical.
How do I buy shares of OncoSec Medical?
Shares of ONCS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OncoSec Medical's stock price today?
One share of ONCS stock can currently be purchased for approximately $1.39.
How big of a company is OncoSec Medical?
OncoSec Medical has a market capitalization of $69.10 million. The biotechnology company earns $-21,440,000.00 in net income (profit) each year or ($1.06) on an earnings per share basis. OncoSec Medical employs 35 workers across the globe.
How can I contact OncoSec Medical?
OncoSec Medical's mailing address is 5820 NANCY RIDGE DRIVE, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 855-662-6732 or via email at [email protected]
MarketBeat Community Rating for OncoSec Medical (NASDAQ ONCS)
MarketBeat's community ratings are surveys of what our community members think about OncoSec Medical and other stocks. Vote "Outperform" if you believe ONCS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONCS will underperform the S&P 500 over the long term. You may vote once every thirty days.
